⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Curium Pharma and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Curium Pharma
↗Boston, USA
Curium Pharma is a global leader in the nuclear medicine industry, specializing in the development, manufacturing, and distribution of diagnostic and therapeutic radiopharmaceuticals. The company provides solutions for oncology, including SPECT and PET imaging, and is increasingly focused on radioligand therapy (RLT) to treat various cancers, particularly prostate cancer and neuroendocrine tumors (NETs).
Headquartered in Boston, Massachusetts, Curium operates a vertically integrated network of manufacturing facilities and nuclear pharmacies across North America, Europe, and Asia. Following its 2025 acquisition of Eczacıbaşı-Monrol, the company significantly expanded its capacity for Lutetium-177 (Lu-177) production and its PET footprint in Eastern Europe and the MENA region.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$4B-$5B
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Private Equity
Investors:CapVest
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial/Late-stage development
Modalities:Radiopharmaceuticals, Radioligand Therapy (RLT)
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Eczacıbaşı-Monrol Nuclear Products Co.
Key Partnerships:PeptiDream (Prostate cancer theranostics in Japan), RadioMedix (In-licensing Detectnet)
COMPETITION
Position:Leader
Competitors:Bayer, ITM Isotope Technologies, Fusion Pharmaceuticals, Clarity Pharmaceuticals, Lantheus Holdings, GE HealthCare
LEADERSHIP
Key Executives:
Ciril Faia - CEO International Markets
Michael Patterson - CEO North America
LINKS
Website:curiumpharma.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Curium Pharma. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.